BIO 2026: Forget dual track—biopharma deals are more complex than ever
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
BIO 2026: Forget dual track—biopharma deals are more complex than ever Read More »
